The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Pierre Fabre
Consulting or Advisory Role - Daiichi Sankyo; Genomic Health; Novartis
Research Funding - G1 Therapeutics (Inst)
Travel, Accommodations, Expenses - AstraZeneca
PARTNER: Randomised, phase II/III trial to evaluate the safety and efficacy of the addition of olaparib to platinum-based neoadjuvant chemotherapy in triple negative and/or germline BRCA mutated breast cancer patients.
 
Jean Abraham
Research Funding - AstraZeneca/MedImmune
 
Anne-Laure Vallier
No Relationships to Disclose
 
Wendi Qian
No Relationships to Disclose
 
Andrea Machin
No Relationships to Disclose
 
Louise Grybowicz
No Relationships to Disclose
 
Stanly Thomas
No Relationships to Disclose
 
Caron Harvey
No Relationships to Disclose
 
Karen McAdam
Honoraria - Novartis; Roche
Consulting or Advisory Role - Roche
 
Luke Hughes-Davies
No Relationships to Disclose
 
Rebecca Roylance
No Relationships to Disclose
 
Ellen Copson
Honoraria - Roche
Speakers' Bureau - Roche
Travel, Accommodations, Expenses - AstraZeneca
 
Elena Provenzano
No Relationships to Disclose
 
Karen Pinilla
Employment - Illumina (I)
 
Emma McMurtry
Employment - AstraZeneca
 
Marc Tischkowitz
No Relationships to Disclose
 
Helena Margaret Earl
Honoraria - Amgen; AstraZeneca; Daiichi Sankyo; Pfizer
Consulting or Advisory Role - AstraZeneca; Celgene; Pfizer; Roche
Research Funding - Roche; Sanofi
Travel, Accommodations, Expenses - Amgen; AstraZeneca; Daiichi Sankyo; Pfizer